Pterostilbene enhances sorafenib’s anticancer effects on gastric adenocarcinoma

Sorafenib has been approved for the treatment of certain cancers in clinic. However, the effects of sorafenib on gastric adenocarcinoma (GAC) were still limited. This study aimed to evaluate both in vitro and in vivo efficacy of sorafenib in combination with pterostilbene (PTE) on the treatment of G...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Tingting, Wang, Chun, Huo, Xinying, He, Ming‐Liang, Chen, Jinfei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7686996/
https://www.ncbi.nlm.nih.gov/pubmed/33047871
http://dx.doi.org/10.1111/jcmm.15795

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7686996/
https://www.ncbi.nlm.nih.gov/pubmed/33047871
http://dx.doi.org/10.1111/jcmm.15795

Ejemplares similares